Abstract
The availability of active monoclonal antibodies has altered the treatment paradigms for patients with non-Hodgkins lymphomas (NHL). Nevertheless, some patients do not respond, while almost all of the others eventually relapse and require additional treatment. Thus, more effective alternatives are needed. Radioimmunotherapy (RIT) is an attractive option because of the inherent radiosensitivity of most NHL. Yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab are the first two radioimmunoconjugates currently available for clinical use. These agents appear comparably active in patients with follicular and low-grade NHL after failure following chemotherapy and/or rituximab. Activity has also been demonstrated against other histologies, including diffuse large B-cell NHL, mantle cell NHL, and transformed NHL. Toxicities primarily include myelosuppression, with a potential risk of treatmentassociated myelodysplastic syndrome and acute myelogenous leukemia. Current clinical trials are attempting to optimize the use of these agents by evaluating them earlier in the course of the disease, and sequenced with a variety of chemotherapy regimens. Hopefully, the rational development of RIT will lead to a prolongation of survival for patients with NHL.
Keywords: radioisotope, ibritumomab, tositumomab, acute myelogenous leukemia (AML), Southwest Oncology Group (SWOG)
Current Drug Targets
Title: Radioimmunotherapy of Non-Hodgkins Lymphomas
Volume: 7 Issue: 10
Author(s): Bruce D. Cheson
Affiliation:
Keywords: radioisotope, ibritumomab, tositumomab, acute myelogenous leukemia (AML), Southwest Oncology Group (SWOG)
Abstract: The availability of active monoclonal antibodies has altered the treatment paradigms for patients with non-Hodgkins lymphomas (NHL). Nevertheless, some patients do not respond, while almost all of the others eventually relapse and require additional treatment. Thus, more effective alternatives are needed. Radioimmunotherapy (RIT) is an attractive option because of the inherent radiosensitivity of most NHL. Yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab are the first two radioimmunoconjugates currently available for clinical use. These agents appear comparably active in patients with follicular and low-grade NHL after failure following chemotherapy and/or rituximab. Activity has also been demonstrated against other histologies, including diffuse large B-cell NHL, mantle cell NHL, and transformed NHL. Toxicities primarily include myelosuppression, with a potential risk of treatmentassociated myelodysplastic syndrome and acute myelogenous leukemia. Current clinical trials are attempting to optimize the use of these agents by evaluating them earlier in the course of the disease, and sequenced with a variety of chemotherapy regimens. Hopefully, the rational development of RIT will lead to a prolongation of survival for patients with NHL.
Export Options
About this article
Cite this article as:
Cheson D. Bruce, Radioimmunotherapy of Non-Hodgkins Lymphomas, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559157
DOI https://dx.doi.org/10.2174/138945006778559157 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1
Current Gene Therapy An Overview of HDAC Inhibitors and their Synthetic Routes
Current Topics in Medicinal Chemistry The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia
Current Drug Targets Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Benzimidazole Heterocycle as a Privileged Scaffold in Antiviral Agents
Mini-Reviews in Organic Chemistry Curcumin: A Natural Product for Diabetes and its Complications
Current Topics in Medicinal Chemistry Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Mini-Reviews in Medicinal Chemistry Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Applications of Mannich Reaction in Total Syntheses of Natural Products
Current Organic Chemistry Anticancer Properties of Asian Water Monitor Lizard (Varanus salvator), Python (Malayopython reticulatus) and Tortoise (Cuora kamaroma amboinensis)
Anti-Cancer Agents in Medicinal Chemistry Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism A Rare Diagnosis in a Patient With Pelvic Pain: Adnexal Schwannoma
Current Medical Imaging Topical Calcineurin Inhibitors, Pimecrolimus and Tacrolimus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Pharmacology and Therapeutic Applications of A3 Receptor Subtype
Current Topics in Medicinal Chemistry Melamine Derivatives - A Review on Synthesis and Application
Current Organic Synthesis Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery